This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Current applications of multiparameter flow cytometry in plasma cell disorders
Blood Cancer Journal Open Access 20 October 2017
-
A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma
Blood Cancer Journal Open Access 16 August 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al. CD20 is associated with a small mature plasma-cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102: 1070–1071.
Linenberger ML . CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005; 19: 176–182.
Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, for the Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. J Clin Oncol 2001; 19: 3244–3254.
Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152: 1655–1665.
Epstein J, Xiao HQ, He XY . Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med 1990; 322: 664–668.
Freeman SD, Kelm S, Barber EK, Crocker PR . Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995; 85: 2005–2012.
Paul SP, Taylor LS, Stansbury EK, McVicar DW . Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000; 96: 483–490.
Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, et al., for the Intergroupe Francophone du Myélome (IFM). Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features and clinical presentation. Blood 2002; 99: 2185–2191.
Acknowledgements
This work was supported by a grant from the Ligue contre le Cancer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Robillard, N., Wuillème, S., Lodé, L. et al. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia 19, 2021–2022 (2005). https://doi.org/10.1038/sj.leu.2403948
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403948
This article is cited by
-
Current applications of multiparameter flow cytometry in plasma cell disorders
Blood Cancer Journal (2017)
-
A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma
Blood Cancer Journal (2013)
-
Reply to ‘Rituximab in CD20 positive multiple myeloma’ by P Moreau et al.
Leukemia (2008)